TopicNeuroscience
Content Overview
12Total items
9ePosters
3Seminars

Latest

SeminarNeuroscience

Investigating the Neurobiology and Neurophysiology of Psilocybin Using Drosophila melanogaster as a Model System

Dotun Adeyinka
Acadia University
Jun 5, 2025
SeminarNeuroscience

Influence of the context of administration in the antidepressant-like effects of the psychedelic 5-MeO-DMT

Romain Hacquet
Université de Toulouse
Aug 29, 2024

Psychedelics like psilocybin have shown rapid and long-lasting efficacy on depressive and anxiety symptoms. Other psychedelics with shorter half-lives, such as DMT and 5-MeO-DMT, have also shown promising preliminary outcomes in major depression, making them interesting candidates for clinical practice. Despite several promising clinical studies, the influence of the context on therapeutic responses or adverse effects remains poorly documented. To address this, we conducted preclinical studies evaluating the psychopharmacological profile of 5-MeO-DMT in contexts previously validated in mice as either pleasant (positive setting) or aversive (negative setting). Healthy C57BL/6J male mice received a single intraperitoneal (i.p.) injection of 5-MeO-DMT at doses of 0.5, 5, and 10 mg/kg, with assessments at 2 hours, 24 hours, and one week post-administration. In a corticosterone (CORT) mouse model of depression, 5-MeO-DMT was administered in different settings, and behavioral tests mimicking core symptoms of depression and anxiety were conducted. In CORT-exposed mice, an acute dose of 0.5 mg/kg administered in a neutral setting produced antidepressant-like effects at 24 hours, as observed by reduced immobility time in the Tail Suspension Test (TST). In a positive setting, the drug also reduced latency to first immobility and total immobility time in the TST. However, these beneficial effects were negated in a negative setting, where 5-MeO-DMT failed to produce antidepressant-like effects and instead elicited an anxiogenic response in the Elevated Plus Maze (EPM).Our results indicate a strong influence of setting on the psychopharmacological profile of 5-MeO-DMT. Future experiments will examine cortical markers of pre- and post-synaptic density to correlate neuroplasticity changes with the behavioral effects of 5-MeO-DMT in different settings.

SeminarNeuroscienceRecording

Psychedelics and the Pharmacology of Consciousness

Olivia Carter
The university of Melbourne
Apr 15, 2021

The study of altered states of consciousness has long had the potential to provide important insight into the nature of consciousness. In recent years there has been a resurgence of research and public interest in atypical or altered states of consciousness. These have focused both on conditions in which consciousness is considered to be impaired due to brain trauma or enhanced in some way through mediation practices or ingestion of psychedelics. The talk will begin with a brief overview of recent scientific approaches to understanding these different types of altered consciousness. The remainder of the talk will focus on lab-based experiments conducted by myself and others looking at the effects of serotoninergic hallucinogens (i.e. psilocybin and LSD) on perceptual and cognitive function. Together this body of research provides important new insights for the scientific study of consciousness and an initial understanding of the neuropharmacological mechanisms underlying conscious experience.

ePosterNeuroscience

Exploring the effects of psilocybin and ketamine (novel antidepressants) on the electroencephalogram (EEG) of C57BL/6 mice: A comparative analysis

Katarzyna Marszałek, Małgorzata Domżalska, John Huxter

FENS Forum 2024

ePosterNeuroscience

COMP360 psilocybin increases high gamma and decreases low theta and delta power and coherence within and between prefrontal cortex and dorsal hippocampus of urethane-anaesthetised rats

Rebecca D. Smausz, Ben Grayson, Christopher Thomas, Jo Neill, John Gigg
ePosterNeuroscience

COMP360 psilocybin restores reward learning impairments in rats caused by chronic interferon-alpha treatment

Justyna K. Hinchcliffe, Christopher Thomas, Caroline Golden, Aslihan Selimbeyoglu, Emma S. Robinson
ePosterNeuroscience

Dosing the Trip: dose-response antagonist-controlled study of persistent psilocybin effects on affective behavior and functional connectivity

Miguel Farinha-Ferreira, Jean-Charles Mariani, Renata Santos, Catarina Miranda-Lourenço, Hugo Simões, Maryna I. Danylyuk, Zsolt Lenkei, Ana M. Sebastião
ePosterNeuroscience

Effects of psilocybin on activity-based anorexia and cognitive flexibility in female rats

Laura K. Milton, Gabriella Farrell, Brian J. Oldfield, Claire J. Foldi
ePosterNeuroscience

Whole-brain cFos mapping of psilocybin effects in the mouse

Youenn TRAVERT-JOUANNEAU, Thomas Topilko, Lotfi Hadjas, Nicolas Renier, Luc Mallet, Linda Simmler, Eric Burguière
ePosterNeuroscience

Acute behavioral and neuronal effects from psilocybin and ketamine in mice

Francesca Sellitti, Lotfi C. Hadjas, Linda D. Simmler

FENS Forum 2024

ePosterNeuroscience

Exploring the effects of psilocybin and ketamine (novel antidepressants) on the electroencephalogram (EEG) of C57BL/6 mice: A comparative analysis

Małgorzata Domżalska, Katarzyna Marszalek, John Huxter

FENS Forum 2024

ePosterNeuroscience

A multiple Arc tagging system to investigate the effect of psilocybin on fear memory extinction

Alessandra Franceschini, Alessia Mastrodonato, Gergely Turi, Christine Ann Denny

FENS Forum 2024

psilocybin coverage

12 items

ePoster9
Seminar3

Share your knowledge

Know something about psilocybin? Help the community by contributing seminars, talks, or research.

Contribute content
Domain spotlight

Explore how psilocybin research is advancing inside Neuroscience.

Visit domain

Cookies

We use essential cookies to run the site. Analytics cookies are optional and help us improve World Wide. Learn more.